Natali _ Mis / Shutterstock.com
10 December 2024NewsAmericasLiz Hockley

Judge denies Intellia bid to throw out suit over $100m Regeneron pact

BlueAllele “plausibly alleged” that some of Intellia’s uses of technology were not reasonably related to FDA approval | Biotech claimed competitor received over $100m from Regeneron for using innovation to research therapeutic candidates.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
13 February 2026   This year’s featured firms and individuals ranked by sister title WIPR, include those instructed on the biggest tech and life sciences cases, as well as the strategists devising global AI patent portfolios.
Americas
10 February 2026   Telehealth platform faces legal action from the Danish pharma giant, as well as FDA pressure over GLP-1 drugs and a drop in shares after discontinuing new product.
Americas
9 February 2026   The Swiss pharma giant moves to protect patents on its billion-dollar cancer therapy following an ANDA filing by a Canadian generics manufacturer.